piR-823 inhibitor treatment induces G1 phase stagnation and decreases G1 phase regulator cyclin D1 and CDK4 expression, consequently inhibiting CRC cell proliferation and promoting cell apoptosis, supporting piR-823 as a therapeutic target [44]. The gene discussed is PIR; the disease is colorectal carcinoma.